Community-Acquired Pneumonia — United Kingdom (General Adult population)
In disease severity assessment
Clinical judgement is essential. The stability of any co-morbid illness and a patient’s social circumstances should be considered.
For all patients seen in the community
Clinical judgement supported by the CRB65 score should be applied when deciding whether to treat at home or refer to hospital.
Patients who have a CRB65 score of 0
Are at low risk of death and do not normally require hospitalisation for clinical reasons.
Patients who have a CRB65 score of 1 or 2
Are at increased risk of death, particularly with a score of 2, and hospital referral and assessment should be considered.
Patients who have a CRB65 score of 3 or more
Are at high risk of death and require urgent hospital admission.
When deciding on home treatment
The patient’s social circumstances and wishes must be taken into account in all instances.
For all patients seen in hospital
The CURB65 score should be interpreted in conjunction with clinical judgement.
Patients who have a CURB65 score of 3 or more
Are at high risk of death. These patients should be reviewed by a senior physician at the earliest opportunity to refine disease severity assessment and should usually be managed as having high severity pneumonia.
Patients with CURB65 scores of 4 and 5
Should be assessed with specific consideration to the need for transfer to a critical care unit (high dependency unit or intensive care unit).
Patients who have a CURB65 score of 2
Are at moderate risk of death. They should be considered for short-stay inpatient treatment or hospital supervised outpatient treatment.
Patients who have a CURB65 score of 0 or 1
Are at low risk of death. These patients may be suitable for treatment at home.
Following hospital admission
Regular assessment of disease severity is recommended. The ‘post take’ round by a senior doctor and the medical team provides one early opportunity for this review.
All patients deemed at high-risk of death on admission to hospital
Should be reviewed medically at least 12 hourly until shown to be improving.
Related Clinical Tools